Funding for this research was provided by:
Innovative Medicines Initiative Joint Undertaking (EMIF grant 115372)
Swedish Research Council
Swedish Alzheimer Foundation
Swedish Brain Foundation
Received: 25 April 2018
Accepted: 9 July 2018
First Online: 28 July 2018
Ethics approval and consent to participate
: The ethical committee of the University of Erlangen-Nuremberg approved the study, and all patients or their caregivers gave their written consent.
: Not applicable.
: PL has received consultation and/or lecture honoraria from IBL International, Fujirebio Europe, AJ Roboscreen, and Roche. KB has served as a consultant or on advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics. KB and HZ are cofounders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. HZ has served on advisory boards of Eli Lilly and Roche Diagnostics and has received travel support from Teva. CS and JP are full-time employees of Boehringer Ingelheim. All remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.